Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

NCT00639483 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00639483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00639483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2003
Completion date
January 31, 2004
Enrollment
270 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia